Novartis (NVS) Stock Falls 3% After Heart Drug Fails Late-Stage Trial

TLDR

• Novartis stock fell over 3% Monday after its experimental drug pelacarsen failed a late-stage cardiovascular trial
• The Lp(a)HORIZON trial involved more than 8,000 patients and missed its primary goal of reducing heart attacks, strokes and cardiovascular deaths
• Pelacarsen did lower lipoprotein(a) blood levels, but this did not translate into fewer cardiovascular events
• The failure raises questions about rival Lp(a)-targeting drugs from Amgen and Eli Lilly, which use a different pathway
• Novartis year-to-date gains now sit at 14%, down from higher levels before Monday’s drop

Novartis stock fell more than 3% in European trading Monday after the company revealed its experimental heart drug pelacarsen failed to meet its primary goal in a major late-stage clinical trial. The drop cut the stock’s year-to-date gain to around 14%.

Novartis AG, NVS

The trial in question is the Lp(a)HORIZON study, which enrolled more than 8,000 patients with elevated levels of lipoprotein(a), a cholesterol-carrying particle in the blood that is linked to heart disease.

… Continue reading the full article at the original source below.